Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corindus Brings In Boston Scientific Exec To Head Sales

This article was originally published in Clinica

Executive Summary

Corindus Vascular Robotics, Inc. has named Gary Lickovitch Vice President of Sales and Service. The appointment was announced Oct. 6, a day after the company said it has secured US FDA clearance for its CorPath robotic system for percutaneous coronary interventions. Lickovitch joins from Boston Scientific, where he was Area Vice-President for the Interventional Cardiology Division and was responsible for sales execution and strategy. He has also held other sales roles at Abbott Vascular and CR Bard. Corindus claims CorPath is the first device of its kind to get US regulatory approval. The robotically-assisted system allows interventional cardiologist to advance stents and guidewires with millimetre-by-millimeter precision; as the cardiologist is performing the procedure behind a console, without the need to wear lead protective equipment, they have more comfort and freedom.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel